ArticleScientific reports2025
Radiomics-based machine-learning method to predict extrahepatic metastasis in hepatocellular carcinoma after hepatectomy: a multicenter study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study investigates the use of CT-based radiomics for predicting extrahepatic metastasis in hepatocellular carcinoma (HCC) following hepatectomy. We analyzed data from 374 patients from two centers (277 in the training cohort and 97 in an external validation cohort). Radiomic features were extracted from contrast-enhanced CT scans. Key features were identified using the least absolute shrinkage and selection operator (LASSO) to compute radiomics scores (radscore) for model development. A clinical model based on risk factors was also created. We developed a combined model integrating both radscore and clinical variables, constructing nomograms for personalized risk assessment. Model performance was compared via the Delong test, with calibration curves assessing prediction consistency. Decision curve analysis (DCA) was employed to assess the clinical utility and net benefit of the predictive models across different threshold probabilities, thereby evaluating their potential value in guiding clinical decision-making for extrahepatic metastasis. Radscore based on CT was an independent predictor of extrahepatic disease (p < 0.05). The combined model showed high predictive performance with an AUC of 87.2% (95% CI: 81.8%-92.6%) in the training group and 86.0% (95% CI: 69.4%-100%) in the validation group. Predictive performance of the combined model significantly outperformed both the radiomics and clinical models (p < 0.05). The DCA shows that the combined model has a higher net benefit in predicting extrahepatic metastases of HCC than the clinical model and radiomics model. The combined prediction model, utilizing CT radscore alongside clinical risk factors, effectively forecasts extrahepatic metastasis in HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.